Literature DB >> 9520344

Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats.

J W Henck1, W R Craft, A Black, J Colgin, J A Anderson.   

Abstract

Atorvastatin is a potent inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate and constitutes the rate-limiting step in the biosynthesis of cholesterol. Steroid hormones derived from cholesterol, as well as mevalonate and its isoprenoid derivatives, provide important contributions to the maternal animal during pregnancy and lactation, as well as to the growth and development of the offspring; these contributions may potentially be influenced by inhibition of HMG-CoA reductase. To investigate the effects of atorvastatin on various aspects of reproduction and development, female Sprague-Dawley rats received 0, 20, 100, or 225 mg/kg daily by gavage from gestation day 7 through lactation day 20. Maternal toxicity, characterized by morbidity/mortality (13%), reduced body weight gain and food consumption, and pathologic lesions in the nonglandular mucosa of the stomach, occurred at 225 mg/kg. Offspring survival at birth and during the neonatal period at 225 mg/kg was reduced relative to control by up to 45%, and 28% of litters had no viable offspring by 10 days postpartum. Additional effects on offspring included reduced body weight during the neonatal and maturation periods (100, 225 mg/kg), delayed appearance of pinnae detachment and incisor eruption (225 mg/kg), impaired rotorod performance (females only; 100, 225 mg/kg), reduced acoustic startle responding (males only; 20, 100, 225 mg/kg), and transient effects on shuttle avoidance (females only; 225 mg/kg). No treatment-related effects were observed on offspring reproduction. In a separate experiment, a single dose of 10 mg/kg atorvastatin administered to female Wistar rats on gestation day 19 or lactation day 13 provided evidence of placental transfer and excretion into the milk. Results of this study indicate that pre- and postnatal administration of atorvastatin to female rats produces developmental toxicity in their offspring via in utero and/or lactational exposure, and in the presence or absence of maternal toxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520344     DOI: 10.1006/toxs.1997.2400

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  10 in total

1.  Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates.

Authors:  Julio Sevillano; Inmaculada C López-Pérez; Emilio Herrera; María Del Pilar Ramos; Carlos Bocos
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

2.  In utero exposure to simvastatin reduces postnatal survival and permanently alters reproductive tract development in the Crl:CD(SD) male rat.

Authors:  Brandiese E J Beverly; Johnathan R Furr; Christy S Lambright; Vickie S Wilson; Barry S McIntyre; Paul M D Foster; Greg Travlos; L Earl Gray
Journal:  Toxicol Appl Pharmacol       Date:  2019-01-11       Impact factor: 4.219

Review 3.  Type 2 diabetes in pregnancy: importance of optimized care before, during and after pregnancy.

Authors:  E Keely
Journal:  Obstet Med       Date:  2008-12-01

Review 4.  Pregnancy and renal failure: the case for application of dosage guidelines.

Authors:  F Keller; M Griesshammer; U Häussler; W Paulus; A Schwarz
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Prevention of pulmonary hypoplasia and pulmonary vascular remodeling by antenatal simvastatin treatment in nitrofen-induced congenital diaphragmatic hernia.

Authors:  Martine Makanga; Hidekazu Maruyama; Celine Dewachter; Agnès Mendes Da Costa; Emeline Hupkens; Geoffrey de Medina; Robert Naeije; Laurence Dewachter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-01-23       Impact factor: 5.464

6.  Use of lipid-lowering agents (statins) during pregnancy.

Authors:  Akiko Hosokawa; Benjamin Bar-Oz; Shinya Ito
Journal:  Can Fam Physician       Date:  2003-06       Impact factor: 3.275

7.  Simvastatin and dipentyl phthalate lower ex vivo testicular testosterone production and exhibit additive effects on testicular testosterone and gene expression via distinct mechanistic pathways in the fetal rat.

Authors:  Brandiese E J Beverly; Christy S Lambright; Johnathan R Furr; Hunter Sampson; Vickie S Wilson; Barry S McIntyre; Paul M D Foster; Gregory Travlos; L Earl Gray
Journal:  Toxicol Sci       Date:  2014-07-23       Impact factor: 4.849

8.  Transfer of rosuvastatin into breast milk: liquid chromatography-mass spectrometry methodology and clinical recommendations.

Authors:  Ei Mon Phyo Lwin; Catherine Leggett; Usha Ritchie; Cobus Gerber; Yunmei Song; William Hague; Sean Turner; Richard Upton; Sanjay Garg
Journal:  Drug Des Devel Ther       Date:  2018-10-29       Impact factor: 4.162

9.  Adverse Maternal, Fetal, and Postnatal Effects of Hexafluoropropylene Oxide Dimer Acid (GenX) from Oral Gestational Exposure in Sprague-Dawley Rats.

Authors:  Justin M Conley; Christy S Lambright; Nicola Evans; Mark J Strynar; James McCord; Barry S McIntyre; Gregory S Travlos; Mary C Cardon; Elizabeth Medlock-Kakaley; Phillip C Hartig; Vickie S Wilson; L Earl Gray
Journal:  Environ Health Perspect       Date:  2019-03       Impact factor: 9.031

10.  Hypoxia-Ischemia Induced Age-Dependent Gene Transcription Effects at Two Development Stages in the Neonate Mouse Brain.

Authors:  Nicolas Dupré; Céline Derambure; Bérénice Le Dieu-Lugon; Michelle Hauchecorne; Yannick Detroussel; Bruno J Gonzalez; Stéphane Marret; Philippe Leroux
Journal:  Front Mol Neurosci       Date:  2020-12-02       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.